WO2001076639A3 - Chemically-modified myelopoietin conjugates - Google Patents
Chemically-modified myelopoietin conjugates Download PDFInfo
- Publication number
- WO2001076639A3 WO2001076639A3 PCT/US2001/011256 US0111256W WO0176639A3 WO 2001076639 A3 WO2001076639 A3 WO 2001076639A3 US 0111256 W US0111256 W US 0111256W WO 0176639 A3 WO0176639 A3 WO 0176639A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- modified
- chemically
- myelopoietin
- conjugates
- mpo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5403—IL-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001289307A AU2001289307A1 (en) | 2000-04-06 | 2001-04-06 | Chemically-modified myelopoietin conjugates |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19549600P | 2000-04-06 | 2000-04-06 | |
US60/195,496 | 2000-04-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001076639A2 WO2001076639A2 (en) | 2001-10-18 |
WO2001076639A3 true WO2001076639A3 (en) | 2002-05-10 |
Family
ID=22721621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/011256 WO2001076639A2 (en) | 2000-04-06 | 2001-04-06 | Chemically-modified myelopoietin conjugates |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2001289307A1 (en) |
WO (1) | WO2001076639A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8969042B2 (en) | 2004-08-19 | 2015-03-03 | Biogen Idec Ma Inc. | Refolding transforming growth factor beta family proteins |
US9138461B2 (en) | 2007-05-01 | 2015-09-22 | Biogen Ma Inc. | Compositions and methods for increasing vascularization |
US11925689B2 (en) | 2008-01-11 | 2024-03-12 | Serina Therapeutics, Inc. | Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA008505B1 (en) * | 2001-11-20 | 2007-06-29 | Фармация Корпорейшн | Chemically modified human growth hormone conjugates |
WO2005085283A1 (en) * | 2004-03-03 | 2005-09-15 | Yamanouchi Pharmaceutical Co., Ltd. | Modified interleukin-11 and medicinal composition containing the same |
US7714114B2 (en) | 2005-02-16 | 2010-05-11 | Nektar Therapeutics | Conjugates of an EPO moiety and a polymer |
TWI501774B (en) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | Treatments for neurological disorders |
EP3042922B1 (en) | 2008-01-11 | 2017-07-19 | Serina Therapeutics, Inc. | Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990012874A2 (en) * | 1989-04-21 | 1990-11-01 | Genetics Institute, Inc. | Cysteine added variants of polypeptides and chemical modifications thereof |
WO1994012639A2 (en) * | 1992-11-24 | 1994-06-09 | G. D. Searle & Co. | Interleukin-3 (il-3) mutant polypeptides |
WO1995021197A1 (en) * | 1994-02-04 | 1995-08-10 | G.D. Searle & Co. | Il-3 variant hematopoiesis fusion protein |
WO1996011953A1 (en) * | 1994-10-12 | 1996-04-25 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US6022535A (en) * | 1993-11-22 | 2000-02-08 | G. D. Searle & Company | Treatment of hematopoietic disorders with fusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors |
-
2001
- 2001-04-06 AU AU2001289307A patent/AU2001289307A1/en not_active Abandoned
- 2001-04-06 WO PCT/US2001/011256 patent/WO2001076639A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990012874A2 (en) * | 1989-04-21 | 1990-11-01 | Genetics Institute, Inc. | Cysteine added variants of polypeptides and chemical modifications thereof |
WO1994012639A2 (en) * | 1992-11-24 | 1994-06-09 | G. D. Searle & Co. | Interleukin-3 (il-3) mutant polypeptides |
US6022535A (en) * | 1993-11-22 | 2000-02-08 | G. D. Searle & Company | Treatment of hematopoietic disorders with fusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors |
WO1995021197A1 (en) * | 1994-02-04 | 1995-08-10 | G.D. Searle & Co. | Il-3 variant hematopoiesis fusion protein |
WO1996011953A1 (en) * | 1994-10-12 | 1996-04-25 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
Non-Patent Citations (2)
Title |
---|
FRANCIS G E ET AL: "PEGYLATION OF CYTOKINES AND OTHER THERAPEUTIC PROTEINS AND PEPTIDES: THE IMPORTANCE OF BIOLOGICAL OPTIMISATION OF COUPLING TECHNIQUES", INTERNATIONAL JOURNAL OF HEMATOLOGY, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 68, no. 1, July 1998 (1998-07-01), pages 1 - 18, XP000791226, ISSN: 0925-5710 * |
ZALIPSKY S: "FUNCTIONALIZED POLY(ETHYLENE GLYCOL) FOR PREPARATION OF BIOLOGICALLY RELEVANT CONJUGATES", BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 6, no. 2, 1995, pages 150 - 165, XP002068523, ISSN: 1043-1802 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8969042B2 (en) | 2004-08-19 | 2015-03-03 | Biogen Idec Ma Inc. | Refolding transforming growth factor beta family proteins |
US9138461B2 (en) | 2007-05-01 | 2015-09-22 | Biogen Ma Inc. | Compositions and methods for increasing vascularization |
US11925689B2 (en) | 2008-01-11 | 2024-03-12 | Serina Therapeutics, Inc. | Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same |
Also Published As
Publication number | Publication date |
---|---|
WO2001076639A2 (en) | 2001-10-18 |
AU2001289307A1 (en) | 2001-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003044056A3 (en) | Chemically-modified human growth hormone conjugates | |
WO2005000359A3 (en) | Chemically-modified human growth hormone conjugates | |
BR0209242A (en) | Starch functional aminopolidiorganosiloxanes | |
DE59905247D1 (en) | AQUEOUS REACTIVE FILLERS (II) | |
WO2001076640A3 (en) | Chemically modified novel erythropoietin stimulating protein compositions and methods | |
WO2001079461A3 (en) | Polypeptides having haloperoxidase activity | |
AU2001241461A1 (en) | Narc-1, novel subtilase-like homologs | |
IL220142A0 (en) | Glycoprotein compositions | |
EP2345671B8 (en) | Optimized fc variants and methods for their generation | |
WO2003000038A3 (en) | Compositions and methods for modulating plant development | |
AU8859498A (en) | Thermosetting aqueous compositions | |
WO2003062375A3 (en) | Stabilizing polypeptides which have been exposed to urea | |
ZA200209049B (en) | Oxidising composition for treating keratin fibres, comprising a particular aminosilicone. | |
WO2004058153A9 (en) | Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476. | |
WO2001076639A3 (en) | Chemically-modified myelopoietin conjugates | |
MXPA03000687A (en) | Flame-resistant polycarbonate compositions. | |
ZA200208766B (en) | Reducing composition for treating keratin fibres, comprising a particular aminosilicone. | |
AU2003302165A1 (en) | Prostate specific antigens, conjugates thereof, methods for their preparation and uses thereof. | |
WO2003000179A3 (en) | Chemically-modified progenipoietin conjugates | |
AU3548201A (en) | Inoculant tolerant fungicidal compositions | |
BG103175A (en) | Water soluble compound and cellulose-containing granulates | |
WO2003057712A3 (en) | Humanized lactoferrin and uses thereof | |
AU6832498A (en) | Substituted benzyl oximino compounds | |
WO2004075028A3 (en) | Systems and methods for variable rebate and incentive programs | |
HK1082510A1 (en) | Promoter to il-18bp, its preparation and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |